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Abstract
Background. Depressive symptoms and inflammation are risk factors for cardiovascular dis-
ease (CVD) and mortality. We investigated the combined association of these factors with the
prediction of CVD and all-cause mortality in a representative cohort of older men and
women.
Methods. We measured C-reactive protein (CRP) and depressive symptoms in 5328 men and
women aged 52–89 years in the English Longitudinal Study of Ageing. Depressive symptoms
were measured using the eight-item Centre for Epidemiological Studies Depression Scale. CRP
was analysed from peripheral blood. Mortality was ascertained from national registers and
associations with depressive symptoms and inflammation were estimated using Cox propor-
tional hazard models.
Results.We identified 112 CVD related deaths out of 420 all-cause deaths in men and 109 CVD
related deaths out of 334 all-cause deaths in women over a mean follow-up of 7.7 years. Men
with both depressive symptoms and high CRP (3–20 mg/L) had an increased risk of CVDmor-
tality (hazard ratio; 95% confidence interval: 3.89; 2.04–7.44) and all-cause mortality (2.40;
1.65–3.48) after adjusting for age, socioeconomic variables and health behaviours. This consid-
erably exceeds the risks associated with high CRP alone (CVD 2.43; 1.59–3.71, all-cause 1.49;
1.20–1.84). There was no significant increase in mortality risk associated with depressive symp-
toms alone in men. In women, neither depressive symptoms or inflammation alone or the com-
bination of both significantly predicted CVD or all-cause mortality.
Conclusions. The combination of depressive symptoms and increased inflammation confers a
considerable increase in CVD mortality risk for men. These effects appear to be independent,
suggesting an additive role.
Introduction
A number of population-based studies have reported that people with depressive symptoms
are at greater risk of mortality (Wulsin et al., 1999; Schulz et al., 2002; Wulsin et al., 2005;
Lasserre et al., 2016), particularly from cardiovascular disease (CVD) (Laursen et al., 2007;
Wu and Kling, 2016; Correll et al., 2017). Even patients with sub-clinical levels of depressive
symptoms, face increased mortality risk (Russ et al., 2012). A robust literature demonstrates
that depressive symptoms increase CVD risk in initially healthy people (Cuijpers and Smit,
2002; Rugulies, 2002; Wulsin and Singal, 2003; Nicholson et al., 2006; Van der Kooy et al.,
2007; Gan et al., 2014) and CVD mortality in those with established disease (Barth et al.,
2004; van Melle et al., 2004; Nicholson et al., 2006; Meijer et al., 2011; Meijer et al., 2013).
Many studies have specifically reported an association between depressive symptoms and mor-
tality in older people. Incident (Penninx et al., 1998; Vinkers et al., 2004; Teng et al., 2013),
intermittent (Geerlings et al., 2002) and chronic depression (Geerlings et al., 2002;
Schoevers et al., 2009; Teng et al., 2013) increase all-cause and CVD mortality in this age
group. However, these findings are not entirely consistent, with some studies reporting no
association (Callahan et al., 1998; Cuijpers, 2001; Hybels et al., 2002; McCusker et al.,
2006). Both persistence and severity of depressive symptoms are associated with increased
mortality risk in older people (White et al., 2015, 2016).
Extensive evidence also exists for an association between depressive symptoms and inflam-
mation (Raison et al., 2006; Irwin and Miller, 2007; Miller et al., 2009; Miller and Raison,
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2016). Longitudinal studies have reported an association between
depressive symptoms and inflammatory biomarkers in otherwise
healthy people (Gimeno et al., 2009; Hamer et al., 2009; Copeland
et al., 2012; Au et al., 2015; Zalli et al., 2015; Bell et al., 2017). In
addition, several meta-analyses show higher levels of inflamma-
tion in depressed patients compared with healthy controls
(Howren et al., 2009; Dowlati et al., 2010; Liu et al., 2012;
Valkanova et al., 2013; Eyre et al., 2016). A recent cumulative
meta-analysis confirmed the robust nature of the depression–
inflammation relationship, showing evidence of increased circu-
lating interleukin-6 and C-reactive protein (CRP) in depressed
compared with non-depressed individuals (Haapakoski et al.,
2015). In patients with CVD, the prevalence of depression is
four times higher than in people from the general population
(Thombs et al., 2006). Depression also shows a high co-morbidity
with a number of major chronic inflammatory or autoimmune
disorders, such as rheumatoid arthritis, multiple sclerosis and dia-
betes type 1 and 2 (Maes et al., 2012). However, it is unclear
whether the increased mortality risk in depressed people is due
to inflammation.
In light of the well-established role of inflammatory processes
in both the pathogenesis of atherosclerosis and the prediction of
cardiac events (Shimbo et al., 2005; Golia et al., 2014; Biasucci
et al., 2017), it has been proposed that inflammation may be
mediating the association between depression and mortality, par-
ticularly in relation to CVD. However, evidence linking inflam-
mation and depressive symptoms with the development of CVD
is inconsistent. A population-based study reported that depressive
symptoms and CRP interact in the prediction of coronary heart
disease (CHD) in men (Ladwig et al., 2005). However, other stud-
ies have demonstrated that depressive symptoms increase CVD
risk independently of inflammatory biomarkers (Empana et al.,
2005; Nabi et al., 2008; Surtees et al., 2008; Davidson et al.,
2009; Hamer et al., 2011), whilst several studies have reported
minimal effects of mediation (Vaccarino et al., 2007; Kop et al.,
2010; Hiles et al., 2015; Hughes et al., 2016). To our knowledge,
only one study has investigated the combined effect of depressive
symptoms and elevated inflammation on CVD development.
Ladwig et al. (2005) showed that combined depressed mood
and high CRP (>3 mg/L) conferred a significantly greater risk
of future cardiac events than either depressed mood or high
CRP alone in older men.
Gender differences have also been observed in the association
between late-life depression and mortality. Several studies report a
greater mortality risk in men (Anstey and Luszcz, 2002; Ryan
et al., 2008; Jeong et al., 2013; Diniz et al., 2014), particularly
for incident depression (Teng et al., 2013) and CVD (Penninx
et al., 1998; Wulsin et al., 1999); whilst women appear to have
increased mortality risk in the presence of chronic or severe
depressive symptoms (Ryan et al., 2008; Teng et al., 2013). An
emerging literature also suggests women are more likely to present
with inflammation when depressed (Bell et al., 2017), potentially
due to higher reactivity to stressful stimuli (Piccinelli and
Wilkinson, 2000). Whether the inflammation and depression
link is particularly important for women is still unknown.
In this study, we used data from the English Longitudinal
Study of Ageing (ELSA) to investigate the combined effects of
depressive symptoms and inflammation on CVD and all-cause
mortality risk in older men and women. In particular, we sought
to investigate whether depressive symptoms moderate the mortal-
ity risk associated with increased inflammation or whether
inflammation could be mediating the association between
depressive symptoms and mortality. In light of previous findings,
we hypothesise that people with both depressive symptoms and
inflammation will have significantly greater mortality risk than
people with depressive symptoms or inflammation alone.
Materials and methods
Study population
The ELSA is a prospective study of a representative sample of
community-dwelling people aged 50 and over living in England.
It collects health, social and economic data. The study com-
menced in 2002, and the sample has been followed up every 2
years. Data are collected using computer-assisted personal inter-
views and self-completion questionnaires, with additional nurse
visits for the assessment of biomarkers every 4 years. Wave 1
included a baseline interview and took place in 2002–2003.
Wave 2 took place in 2004–2005 and consisted of an interview
and a health examination that included a collection of blood sam-
ples. At wave 1, the sample consisted of 11 391 study members
and was deemed to be nationally representative. For more infor-
mation on ELSA see http://www.elsa-project.ac.uk/.
Our study included 5328 people, aged 52–89 years, from an
initial cohort of 8670 who participated in the interview at wave
2. We excluded 1084 individuals who did not participate in the
health examination survey, 134 who did not consent for their
vital status data to be included, 1411 who were unable to provide
a blood sample and 330 individuals whose CRP values were
unavailable or not reliable. The latter included samples which
were lost in the post, received later than 5 days after collection,
considered unusable by the laboratory or of insufficient amount
to be analysed. Detailed information about how the ELSA data
were collected and processed into their current format and
about how each variable was coded is available at https://dis-
cover.ukdataservice.ac.uk/series/?sn=200011. We also excluded
155 participants from the analysis because their CRP levels were
⩾20 ml/L, allowing for the elimination of individuals with acute
inflammation, while another 229 participants were excluded
because of missing values in the covariates.
Participants included and excluded from the analysis did not
differ significantly in terms of sex. The group included in the ana-
lysis was younger, less likely to be depressed, more likely to be
married, more educated and wealthier than the group who was
excluded.
Assessment of inflammation
Blood samples were taken by the study nurse at wave 2 and serum
CRP was analysed by Royal Victoria Infirmary, Newcastle. High
sensitivity plasma CRP level was dichotomised into two categor-
ies: <3 mg/L was defined as normal and 3–20 mg/L was defined as
high. This cut off point is based on guidelines from the Centre for
Disease Control and Prevention and the American Heart
Association, suggesting that plasma CRP values of >3.0 mg/L
might be predictive of CVD (Pearson et al., 2003).
Assessment of depressive symptoms
Depressive symptoms were measured at wave 2 (2004–2005) using
the eight-item Centre for Epidemiological Studies Depression
Scale 8 (CES-D8) which is a self-report questionnaire designed
to measure depressive symptomatology in the general population
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(Radloff, 1977). Respondents were asked how often they felt
depressed, felt that everything was an effort, slept restlessly,
were happy, felt lonely, enjoyed life, felt sad, and could not get
going. The two positive items (‘was happy’ and ‘enjoyed life’)
are reverse coded, so a higher score here also indicates a more
depressed mood. We subsequently derived a summary CES-D
score by adding responses to all eight dichotomous questions
(possible range: 0–8). The exact wording of the different items
can be found in appendix 1. The eight-item abbreviated version
of the CES-D has been widely used, is internally consistent, has
been validated in both the general population (Van de Velde
et al., 2009) and older adults, and shows a comparable construct
of depression across 11 different countries (Missinne et al., 2014).
The presence of depressive symptoms was defined as CES-D ⩾4
as per previous publications (Steffick, 2000; Hamer et al., 2012;
Mhaoláin et al., 2012; Demakakos et al., 2013; Malgaroli et al.,
2017). This conservative threshold has been found to produce
comparable results to the >16 cut off on the well-validated
20-item CES-D scale (Radloff, 1977; Steffick, 2000).
Depressive symptoms and inflammation as a combined
variable
In order to ascertain whether the combination of depressive
symptoms and inflammation predicts mortality, the variables
based on wave 2 assessments were combined and four new vari-
ables were computed: ‘no depressive symptoms/low inflamma-
tion’, ‘no depressive symptoms/high inflammation’, ‘depressive
symptoms/low inflammation’ and ‘depressive symptoms/high
inflammation’.
Mortality
Mortality was ascertained for a mean 7.7 year period for consent-
ing study members (5328) by linking to the UK National Health
Service mortality register up until 12 November 2015. In England,
all deaths need to be registered within 5 days, therefore partici-
pants not registered as dead were assumed to be alive. Deaths
were classified according to International Classification of
Diseases (ICD) 10th Edition. Deaths with ICD10 codes I00 to
I99 were classified as cardiovascular deaths.
Covariates
All covariates were collected at wave 2 (2004–2005) with the
exception of education and sex which were collected at wave
1. All covariates where determined by self-report, with the excep-
tion of body mass index (BMI). Age was treated as a continuous
variable. Socioeconomic status (SES) was operationalised by using
marital status (married/cohabiting v. not married/single/divorced),
level of education (degree/higher/A-level, GCSE/O-level/other, no
qualifications) and total wealth in tertiles. Total wealth was defined
from the sum of financial, physical (e.g. businesses, land) and hous-
ing wealth, minus debts and pension payments. Health behaviours
included: smoking (never smoked, ex-smoker, current smoker) and
BMI (<25 kg/m2, 25–29.99 kg/m2, >30 + kg/m2) (Banks et al.,
2006). The presence of chronic diseases were added as separate
variables and defined as yes/no. They were calculated as lifetime
self-reported physician diagnoses of chronic conditions (i.e. CVD
(myocardial infarction and stroke), chronic lung disease, cancers
(of any site) and emotional, nervous and psychiatric problems).
The covariates have been included because they have all been
shown to be associated with mortality and are therefore potential
confounders (Marmot et al., 2012; Wong, 2014; Pletcher and
Moran, 2017). Furthermore, health behaviours such as smoking
and BMI were included as they have been shown to mediate the
relationship between depression and mortality (Joynt et al., 2003).
Statistical analysis
Differences between the characteristics of the participants
included and excluded from the analysis were analysed. Baseline
characteristics were analysed by depressive symptoms and inflam-
mation levels. The association of depressive symptoms and
inflammation levels (separately and in combination) with CVD
and all-cause mortality were assessed by Cox proportional
hazards regression models. The proportionality assumption was
tested using Nelson–Aalen cumulative hazard curves and
Schoenfeld residuals. We inspected the plots and the global test
( p = 0.8052) confirming that we do not have a violation of the
proportional assumption. Survival time was measured in months,
from the date of interview in wave 2 (2004–2005) to the date of
death or 12 November 2015, whichever was first. Kaplan Meier
survival curves are available online (online Supplementary
Fig. S1).
We investigated whether there were significant interactions
between age or sex and depression/inflammation categories in
order to determine whether the association between depression/
inflammation levels and mortality varied according to age or
between men and women. We used the likelihood ratio test to
compare the goodness of fit of a stratified model. We found no
interaction between sex and depressive symptoms, however, we
did find that the association between inflammation and mortality
varied significantly by sex ( p value = 0.013). There was also an age
interaction between inflammation and mortality, however, this
disappeared once we stratified our analysis by sex, therefore, we
only present the sex-stratified analyses. We first fitted a basic
unadjusted model, which was followed by an age-adjusted
model. We then additionally adjusted for socioeconomic vari-
ables, health behaviours and chronic diseases.
To investigate moderation we tested whether a multiplicative
interaction between depressive symptoms and inflammation was
significantly associated with mortality. To investigate mediation,
we first examined the association between depressive symptoms
and mortality and then added inflammation to see how much
of the association was explained. All analyses were performed
using STATA 13.0 (StataCorp LP, College Station Texas).
Results
There were 420 all-cause male deaths (including 112 CVD
related) over mean of 7.6 years follow-up and 334 all-cause female
deaths (including 109 CVD related) over a mean of 7.8 years
follow-up. Out of a total of 5328 people, we identified 420 all-
cause deaths in men and 334 in women during 18 594 and 22
519 person-years, respectively.
Table 1 represents social-demographic characteristics in
depression/inflammation categories in men and women separ-
ately. Men and women with concurrent depressive symptoms
and high inflammation were more likely to be poorer, less edu-
cated, more likely to smoke, have a higher BMI and were more
likely to have chronic lung disease and emotional, nervous and
psychiatric problems. There were no significant overall differences
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Table 1. Baseline characteristics of men and women aged 52–89 years by depressive symptoms and inflammation level
Men Women
Depressive symptoms/inflammation level
No depressive
symptoms/
normal CRP
No
depressive
symptoms/
high CRP
Depressive
symptoms/
normal CRP
Depressive
symptoms/
high CRP p value
No depressive
symptoms/
normal CRP
No
depressive
symptoms/
high CRP
Depressive
symptoms/
normal CRP
Depressive
symptoms/
high CRP p value
Number 1551 668 132 98 1542 864 275 198
Mean age (SD) (years) 64.9 (8.8) 67 (9.1) 64.5 (9.1) 66.9 (9.9) <0.001 65 (9.0) 66.5 (9.2) 67.3 (10.3) 67.4 (9.7) <0.001
Marital status (%)
Married 1252 (80.7) 501 (75) 79 (59.9) 60 (61) <0.001 1023 (66.3) 530 (61.3) 128 (46.6) 83 (41.9) <0.001
Not married 299 (19.3) 167 (25) 53 (40) 38 (39) 519 (33.7) 334 (38.7) 147 (53.5) 115 (58.1)
Education (%)
Degree/Higher/A-level 700 (45.1) 228 (34.1) 43 (32.6) 27 (27.6) <0.001 458 (29.7) 191 (22.1) 51 (18.6) 39 (19.7) <0.001
GCSE/O-level/Other
qualification
444 (28.6) 203 (30.4) 37 (28) 27 (27.6) 555 (36) 281 (32.5) 98 (35.6) 53 (26.8)
No qualification 407 (26.2) 237 (35.5) 52 (39.4) 44 (44.9) 529 (34.3) 392 (45.4) 126 (45.8) 106 (53.54)
Total wealth (%)
Richest 688 (44.4) 203 (30.4) 40 (30.3) 17 (17.4) <0.001 681 (44.2) 228 (26.4) 73 (26.6) 28 (14.1) <0.001
Intermediate 531 (34.2) 252 (37.7) 35 (26.5) 35 (35.7) 486 (31.5) 323 (37.4) 89 (32.4) 82 (41.4)
Poorest 332 (21.4) 213 (31.9) 57 (43.2) 46 (46.9) 375 (24.3) 313 (36.2) 113 (41.1) 88 (44.4)
Smoking status (%)
Never a smoker 496 (32) 149 (22.3) 34 (25.8) 15 (15.3) <0.001 743 (48.2) 379 (43.9) 107 (38.9) 65 (32.8) <0.001
Ex-smoker 894 (57.6) 383 (57.3) 73 (55.3) 57 (58.2) 634 (41.1) 355 (41.1) 126 (45.8) 79 (39.9)
Current smoker 161 (10.4) 136 (20.4) 25 (18.9) 26 (26.5) 165 (10.7) 130 (15.1) 42 (15.3) 54 (27.3)
Body Mass Index
<25 kg/m2 (%) 403 (26.8) 123 (19.3) 35 (27.8) 20 (23.5) <0.001 606 (40.5) 121 (14.9) 98 (37) 32 (17.5) <0.001
25–29.99 kg/m2 (%) 777 (51.7) 306 (48.1) 59 (46.8) 32 (37.7) 628 (42) 285 (35) 113 (42.6) 65 (35.5)
>30 + kg/m2 (%) 323 (21.5) 207 (32.6) 32 (25.4) 33 (38.8) 262 (17.5) 408 (50.1) 54 (20.4) 86 (47)
Chronic disease
CVD (% yes) 115 (7.41) 61 (9.13) 14 (10.61) 14 (14.29) 0.052 48 (3.11) 31 (3.59) 14 (5.09) 14 (7.07) 0.026
Cancer (% yes) 85 (5.48) 46 (6.89) 7 (5.30) 11 (11.22) 0.093 139 (9.01) 58 (6.73) 26 (9.49) 14 (7.07) 0.191
Lung diseasea (% yes) 78 (5.03) 70 (10.48) 10 (7.58) 18 (18.37) <0.001 55 (3.57) 69 (8.00) 31 (11.31) 33 (16.67) <0.001
Psychiatricb (% yes) 81 (5.22) 32 (4.79) 25 (18.94) 22 (22.45) <0.001 159 (10.31) 81 (9.40) 58 (21.17) 51 (25.76) <0.001
SD = standard deviation. Statistical tests examined the associations of demographic variables with depressive symptoms/inflammation levels. ANOVA tests were used for continuous variables and Chi-square tests were used for categorical variables.
aChronic lung disease.
bEmotional, nervous or psychiatric diseases.
4
Sam
antha
Law
es
et
al.
https://w
w
w
.cam
bridge.org/core/term
s. https://doi.org/10.1017/S003329171800209X
D
ow
nloaded from
 https://w
w
w
.cam
bridge.org/core. U
C
L, Institute of Education, on 25 Sep 2018 at 14:17:48, subject to the C
am
bridge C
ore term
s of use, available at
in the frequency of CVD or cancer between depression/inflamma-
tion levels in either men or women. (Table 1).
Depressive symptoms and inflammation as a combined
predictor of CVD mortality
In men, depressive symptoms alone were not associated with any
significant increase in the risk of death, whilst high inflammation
was associated with a 238% (HR: 3.38; 95% CI 2.23–5.10) increased
risk. Men with both depressive symptoms and high inflammation
had a 584% (HR: 6.84; 95% CI 3.71–12.6) increased CVDmortality
risk. This association remained significant after adjustment for age,
SES and health behaviours, with men who had both depressive
symptoms and high inflammation demonstrating a 289% (HR:
3.89; 95% CI 2.04–7.44) increased risk of death ( p value <0.001)
(Table 2 and Fig. 1). In women, the associations were more modest
and failed to reach significance (Table 2).
Depressive symptoms and inflammation as a combined
predictor of all-cause mortality
In men, the direction of results was similar for all-cause mortality.
Depressive symptoms alone were not associated with a significant
increase in the risk of death, whilst high inflammation was asso-
ciated with a 91% (HR: 1.91; 95% CI 1.55–2.36) increased risk,
compared with men with neither. Men with both depressive
symptoms and high inflammation had a 241% (HR: 3.41; 95%
CI 2.39–4.86) increased mortality risk. This association was atte-
nuated after adjustment for age, SES and smoking. However, the
association remained significant, with men who had both depres-
sive symptoms and high inflammation demonstrating a 140%
(HR: 2.40; 95% CI 1.65–3.48) increased risk of death (Fig. 1).
The results for women were different. In the unadjusted
model, both depressive symptoms and high inflammation separ-
ately increased the risk of death by 85% (HR: 1.85; 95% CI 1.32–
2.59) and 48% (HR: 1.48; 95% CI 1.16–1.90), respectively. The
combination of both depressive symptoms and high inflammation
increased the risk to 89% (HR: 1.89; 95% CI 1.29–2.76), only mar-
ginally more than depressive symptoms alone. The increased risk
of depressive symptoms and high inflammation to all-cause mor-
tality in women was explained by age as after adjustments the risk
was no longer significant (Table 2).
Effects of moderation and mediation
Moderation analysis showed that an interaction term of depressive
symptoms by inflammation was not significantly associated with
mortality in all categories: all-cause mortality in men ( p = 0.426);
all-cause mortality in women ( p = 0.155); CVD mortality in men
( p = 0.868) and CVD mortality in women ( p = 0.481). This sug-
gests that the mortality risk conferred by increased levels of
inflammation is not further augmented by depressive symptoms.
Mediation analysis showed that the strength of the association
between depressive symptoms and mortality was not reduced by
including inflammation, suggesting a direct effect of depressive
symptoms on mortality risk (online Supplementary Table S1).
Discussion
In this study, we examined the combined effect of depressive symp-
toms and inflammation on CVD and all-cause mortality in a large
cohort of older adults. Our findings suggest that older men, with
both depressive symptoms and high levels of inflammation, have
an increased risk of CVD and all-cause mortality compared with
men with depressive symptoms or inflammation alone. In addition,
our study demonstrates the independent effects of depressive symp-
toms and inflammation on mortality, finding no evidence of either
moderation or mediation. To our knowledge, our study is the first
to investigate the combined effect of depressive symptoms and
inflammation of mortality in both men and women.
Depression, inflammation and mortality
We demonstrated an increased risk of all-cause mortality in the
comparison between men with high and low baseline levels of
inflammation. The addition of depression to the model increased
the risk substantially suggestive of a particularly high-risk pheno-
type in men. This supports findings in healthy, older men show-
ing that high inflammation predicted cardiovascular events only
in people with depressed mood (Ladwig et al., 2005). These find-
ings suggest that depression and inflammation might cause CVD
through separate physiological pathways, such as elevated
interleukin-6 upstream of CRP (Ridker, 2016), triglycerides
(Parekh et al., 2017), cortisol as a result of stress-induced hyper-
activity of the hypothalamic-pituitary-adrenal axis (Jokinen and
Nordstrom, 2009), endothelial dysfunction (Chen et al., 2011)
and platelet activation (Williams et al., 2014).
Our study found no significant interaction between depressive
symptoms and inflammation on mortality and no effect of medi-
ation, a finding which is supported by other studies but not by all.
To our knowledge, there is only one other study which looked at
the potential synergistic effect of depressive symptoms and
inflammation in the prediction of cardiovascular events. Ladwig
showed a significant interaction between depressive symptoms
and inflammation in the prediction of cardiovascular events, sug-
gesting a shared underlying mechanism (Ladwig et al., 2005).
These authors, however, have only investigated men.
Most previous studies investigating the effects of inflammation
mediating the association between depression and all-cause or
CVD mortality showed either no or small effects. Similar to our
study, Empana et al., (2005) showed that men with depressive
symptoms had a 53% increase in the odds of CHD and the asso-
ciation remained unchanged when inflammatory markers were
added to the model. Davidson et al., 2009 found that depressive
symptoms increased the risk of incident CHD; this risk was not
explained by increased inflammation in either men or women.
Nabi et al., 2008 also found an association between psychological
distress and incident CHD which remained after adjustment for
inflammatory markers. Contrary to our study and the studies
cited above, there has also been reports of mediation. Hughes
et al., (2016) reported an association between depressive symp-
toms and all-cause mortality which was partly explained by
inflammation (CRP 7.3%). Inflammation partly mediated the pre-
dictive value of depressive symptoms by 6.5% in cardiovascular
mortality risk (Kop et al., 2010), and by 8.1% in cardiovascular
hospitalization (Hiles et al., 2015). This supports the knowledge
that other pathways are also involved in the depression and mor-
tality link.
Effect of gender on the link between depressive symptoms,
inflammation and mortality
Clear sex-specific differences were observed in the inter-
relationships of depressive symptoms, inflammation and
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Table 2. Association between depressive symptoms/inflammation levels and all-cause and cardiovascular mortality by sex+
Men Women
Depressive symptoms/inflammation level
No depressive
symptoms/
normal CRP
No depressive
symptoms/high
CRP
Depressive
symptoms/normal
CRP
Depressive
symptoms/high
CRP
No depressive
symptoms/
normal CRP
No depressive
symptoms/high
CRP
Depressive
symptoms/normal
CRP
Depressive
symptoms/high
CRP
Model
All-cause
mortality
Model 1 HR (95%
CI, p values)a
1.00
(reference)
1.91 (1.55–2.36)
<0.001
1.42 (0.93–2.17)
0.104
3.41 (2.39–4.86)
<0.001
1.00
(reference)
1.48 (1.16–1.90)
0.002
1.85 (1.32–2.59)
<0.001
1.89 (1.29–2.76)
0.001
Model 2 HR (95%
CI, p values)b
1.00
(reference)
1.63 (1.32–2.00)
<0.001
1.47 (0.97–2.25)
0.072
3.03 (2.12–4.32)
<0.001
1.00
(reference)
1.23 (0.96–1.57)
0.104
1.34 (0.95–1.87)
0.093
1.44 (0.98–2.10)
0.060
Model 3 HR (95%
CI, p values)c
1.00
(reference)
1.54 (1.25–1.90)
<0.001
1.29 (0.84–1.98)
0.242
2.59 (1.80–3.74)
<0.001
1.00
(reference)
1.18 (0.92–1.51)
0.199
1.27 (0.90–1.78)
0.168
1.30 (0.89–1.92)
0.176
Model 4 HR (95%
CI, p values)d
1.00
(reference)
1.49 (1.20–1.84)
<0.001
1.27 (0.83–1.96)
0.273
2.40 (1.65–3.48)
<0.001
1.00
(reference)
1.09 (0.84–1.41)
0.536
1.18 (0.84–1.66)
0.336
1.15 (0.77–1.70)
0.501
Model 5 HR (95%
CI, p values)e
1.00
(reference)
1.46 (1.18–1.81)
<0.001
1.24 (0.80–1.90)
0.337
2.09 (1.43–3.07)
<0.001
1.00
(reference)
1.11 (0.85–1.44)
0.436
1.12 (0.79–1.58)
0.336
1.10 (0.74–1.65)
0.629
Cardiovascular
disease mortality
Model 1 HR (95%
CI, p values)a
1.00
(reference)
3.38 (2.23–5.10)
<0.001
1.86 (0.79–4.38)
0.159
6.84 (3.71–12.6)
<0.001
1.00
(reference)
1.45 (0.96–2.2)
0.079
1.27 (0.66–2.44)
0.417
1.29 (0.61–2.71)
0.508
Model 2 HR (95%
CI, p values)b
1.00
(reference)
2.81 (1.86–4.26)
<0.001
1.91 (0.81–4.51)
0.140
5.78 (3.13–10.68)
<0.001
1.00
(reference)
1.14 (0.75–1.73)
0.540
0.81 (0.42–1.56)
0.531
0.93 (0.44–1.97)
0.857
Model 3 HR (95%
CI, p values)c
1.00
(reference)
2.56 (1.68–3.89)
<0.001
1.51 (0.63–3.62)
0.354
4.50 (2.39–8.47)
<0.001
1.00
(reference)
1.09 (0.71–1.67)
0.685
0.76 (0.39–1.46)
0.407
0.84 (0.40–1.80)
0.658
Model 4 HR (95%
CI, p values)d
1.00
(reference)
2.43 (1.59–3.71)
<0.001
1.50 (0.63–3.60)
0.361
3.89 (2.04–7.44)
<0.001
1.00
(reference)
0.92 (0.59–1.44)
0.715
0.69 (0.35–1.33)
0.267
0.69 (0.32–1.50)
0.353
Model 5 HR (95%
CI, p values)e
1.00
(reference)
2.42 (1.58–3.69)
<0.001
1.44 (0.60–3.46)
0.413
3.25 (1.66–6.40)
0.001
1.00
(reference)
0.96 (0.62–1.50)
0.866
0.69 (0.35–1.35)
0.275
0.68 (0.32–1.49)
0.338
HR = hazard ratio; CI = confidence interval; CRP = C-reactive protein. Cox regression survival analysis models, stratified by sex, are adjusted as follows:
aInflammation and depressive symptoms as main effects.
bAs model 1, plus adjustment for age.
cAs model 2, plus adjustment for socioeconomic variables (marital status, level of education, total wealth).
dAs model 3, plus adjustment for health behaviours (smoking, body mass index).
eA model 4, plus individually adjustment for chronic diseases (cardiovascular disease, cancers, chronic lung disease and emotional, nervous and psychiatric problems).
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mortality in this study. The combination of depressive symptoms
and inflammation only conferred an increased mortality risk in
men. A previous population cohort study investigating inflamma-
tion and mortality also showed sex differences. Ahmadi-Abhari
et al., reported that high levels of CRP increased mortality risk
in men at lower clinical threshold categories than in women,
most notably for CVD mortality (2013). A similar trend has
also been observed in the development of CHD. In a study of
older men and women, Cushman et al. showed that the presence
of high inflammation was predictive of CHD in men with inter-
mediate Framingham Risk Scores, whereas it only became pre-
dictive of CHD in women with a high Framingham risk (2005).
Furthermore, a large meta-analysis showed that inflammation
only discriminated 10-year risk of cardiovascular events in men,
but not in women (Kaptoge et al., 2012). Some reports on the
association between depression and inflammation also support
our findings, although not all. Two large population cohort stud-
ies have shown that major depression/depressive symptoms and
inflammation are more strongly associated in men than in
women (Ford and Erlinger, 2004; Elovainio et al., 2009).
However in contrast, in a study of 508 healthy adults, depressive
symptoms were only associated with inflammation in women, not
in men (Ma et al., 2010). Furthermore, a study of women with
suspected coronary ischemia demonstrated a robust association
between depressive symptoms and inflammation which was not
explained by CVD risk factors (Vaccarino et al., 2007).
Further speculation on gender differences is inspired by a recent
review by Raison and Miller (2017). The authors propose that in
evolutionary terms, depression may have provided an adaptive
advantage to women. Inflammation was detrimental to fertility in
ancestral environments (Van Bodegom et al., 2007; Schaller and
Park, 2011; Kobayashi et al., 2013). Depressive symptoms promoted
sickness behaviours (e.g. lethargy, psychomotor slowing and social
withdrawal) which provided increased protection against pathogens
(e.g. by conserving energy for an immune response), thereby redu-
cing the need for a high inflammatory response. This is supported
by findings which show that women demonstrate increased levels
of depression in response to inflammatory challenge compared
with men (Moieni et al., 2015; Udina et al., 2012). If women are
more likely to develop depression in response to immune activation
then it is possible that the presence of depressive symptoms is likely
to reflect less severe underlying biological pathology compared with
men and consequently lower mortality risk. Whilst this explanation
is intuitively appealing, further research is required to confirm gen-
der specific immune mechanisms in depression.
Another possible explanation for our observed sex differences
is the influence of sex hormones, particularly the protective effect
of oestrogen on the heart. In people under 75, the incident of
cardiovascular-related death is lower in women than in men
(British Heart Foundation, 2014), with the development of ath-
erosclerosis occurring post menopause in 95% of women
(Fairweather, 2014). Even at 65–74 years of age, almost two dec-
ades after the average occurrence of menopause, women have a
substantially lower incidence of CVD compared with men. This
suggests that former exposure to endogenous estrogen may be
atheroprotective long after menopause. Women have also been
shown to have longer telomeres than men (Gardner et al.,
2014). Shorter telomeres have been associated with early death
in the general population (Weischer et al., 2012) although find-
ings are inconsistent (Bojesen, 2013). Telomere length has been
more robustly associated with CHD, independently of traditional
vascular risk factors (Haycock et al., 2014). It is not yet under-
stood exactly why women differ from men in the development
of CHD, however to date women have been underrepresented
in cardiovascular trials, resulting in a bias towards factors which
are relevant to disease aetiology in men (Fairweather, 2014).
Current National Institute for Health and Clinical Excellence
(NICE) guidelines recommend the use of the QRISK2 risk assess-
ment tool to assess risk for the primary prevention of CVD in both
men and women up to 84 years (National Institute for Health and
Care Excellence, 2014). There has been some debate as to whether
or not the addition of circulating inflammatory markers, such as
CRP, should now be included in screening measures for cardiovascu-
lar risk (Pearson et al., 2003; Peters et al., 2013). Themain uncertainty
seems to be whether the modest increases in risk associated with
higher inflammation can produce significant health benefits. This
is understandable when considering that population studies have
shown that CRP is a relatively moderate predictor of CVD risk, yield-
ing an odds ratio of 1.5 when comparing the top baseline tertile with
the bottom (Danesh et al., 2004). In addition, when compared with
traditional risk factors, such as smoking and total cholesterol, CRP
only slightly improved their predictive value. Our study demonstrates
that men with comorbid depressive symptoms and high inflamma-
tion constitute a clinically meaningful risk category. In light of
Fig. 1. Adjusted hazard ratios for CVD and all-cause mortality according to levels of depressive symptoms and inflammation in men. * Statistically significant at
P<0.001.CVD = Cardiovascular disease; CRP = C-reactive protein. Hazard ratios are adjusted for age, socioeconomic variables (marital status, level of education, total
wealth), health behaviours (smoking, body mass index) and chronic diseases (cardiovascular disease, cancers, chronic lung disease and emotional, nervous and
psychiatric problems). n = 5,328.
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these findings, it might be worth considering inflammation as a car-
diovascular risk factor in depressed men. This could help identify
patients who may benefit from targeted prophylactic intervention,
improving screening efficacy and cardiovascular outcomes.
Study strengths and limitations
The strengths of our study include the prospective design, the pres-
ence of both women and men and the nationally representative
nature of the ELSA cohort. Despite this, our study also has limita-
tions. The first limitation of this study is that we measured depres-
sive symptoms and inflammation at only one-time point at wave 2
(2004–2005) and did not investigate any change in levels at a later
point. This design was chosen in order to maximise the number of
participants with inflammation and depressive symptoms at base-
line and to allow a longer follow-up period to capture mortality.
Nevertheless, we did not find an association of depressive
symptoms and mortality in the absence of inflammation. In a
recent study using the same cohort, which considered depressive
symptoms across several years, a dose-response association was
observed between persistence of depressive symptoms across
time and mortality risk (White et al., 2016). Similar to these find-
ings, data from the Longitudinal Aging Study Amsterdam also
found that transient depressive episodes did not predict mortality
although chronic depression did (Geerlings et al., 2002). Secondly,
we also did not control for medication use in our analysis, as this
data was not available. Statins, for example, present anti-
inflammatory effects (Antonopoulos et al., 2012) and therefore
medication use may have interfered with current findings.
Thirdly, our study had a smaller proportion of female deaths
compared to male deaths and therefore it is unclear whether
our lack of association in women reflects an absence of an effect
or is a result of insufficient power. The only closest previous study
to date investigated combined depressive symptoms and inflam-
mation in the development of CVD and was restricted to men.
Finally, in our study depressive symptoms were measured by an
8 item self-reported questionnaire, rather than a diagnostic inter-
view. Short scales such as this have previously been criticised for a
lack of specificity. To address this, we defined depressive symp-
toms using a conservative cut-off of 4, which increases the mea-
sure’s ability to discriminate between true and false positives.
In conclusion, we demonstrated that men with concurrent
depressive symptoms and increased inflammation constitute a
high-mortality risk phenotype. This risk is particularly high for
cardiovascular-related death. These findings have clinical implica-
tions for the treatment and prevention of depression and inflam-
mation in men. Subgroups of depressed individuals with
comorbid inflammation may benefit from additional anti-
inflammatory pharmacotherapy. Further research is needed to
investigate whether combined interventions improve outcomes.
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be found at https://doi.org/10.1017/S003329171800209X
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